The prognostic value of immune checkpoints in oral squamous cell carcinoma

.

.

Sieviläinen M, Almahmoudi R, Al-Samadi A, Salo T, Pirinen M, Almangush A.

.

Oral Dis. 2019 Sep;25(6):1435-1445. doi: 10.1111/odi.12991. Epub 2018 Nov 12.

Abstract

BACKGROUND: Despite the importance of immune checkpoints in immunotherapy, the prognostic value of these molecules remains controversial in oral squamous cell carcinoma (OSCC). We performed a systematic review to investigate the prognostic significance of the immune checkpoints in OSCC. MATERIALS: A systematic search was conducted in Ovid Medline, Scopus and Cochrane libraries, and all studies that evaluated the prognostic significance of immune checkpoints in OSCC were systematically retrieved. RESULTS: Twelve immune checkpoints/modulators were studied for their prognostic values in OSCC patients between 1985 and 2017. Seven immune checkpoints (FKBP51, B7-H4, B7-H6, ALHD1, PD-L1, B7-H3 and IDO1) were reported to be associated with poor patients’ survival in at least one study, and five (CTLA-4, TLT-2, VISTA, PD-L2 and PD-1) did not have a significant prognostic value. PD-L1 results were controversial as it was reported to be associated with both better and worse patients’ survival. CONCLUSIONS: Even though immune checkpoint markers had high expectation for OSCC prognostication, our systematic review revealed that the majority of them had been studied only once. The other molecules, which had been studied more than once, had controversial findings, except B7-H3. CI – ¬© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.

Keywords: .

Link/DOI: 10.1111/odi.12991